Search Results for "naloxone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for naloxone. Results 11 to 14 of 14 total matches.
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
in sublingual formulations with
and without the opioid antagonist naloxone.2
BUPRENORPHINE ― Buprenorphine ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
but efficacy data
with buprenorphine/
naloxone are limited
Buprenorphine
monotherapy is
considered safe ...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 doi:10.58347/tml.2023.1684b | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
concurrently with other CNS depressants, especially
benzodiazepines.
The opioid antagonist naloxone should ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
An Epinephrine Nasal Spray (neffy) for Anaphylaxis
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
is the same as that used in several other FDA-approved
nasal sprays, including naloxone (Narcan ...
The FDA has approved an epinephrine nasal spray
(neffy – ARS Pharma) for emergency treatment
of type 1 hypersensitivity reactions including
anaphylaxis in patients who weigh ≥30 kg. It is
the first noninjectable epinephrine product to be
approved for this indication.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):163-4 doi:10.58347/tml.2024.1713b | Show Introduction Hide Introduction